Faisal Khurshid
Stock Analyst at Leerink Partners
(4.51)
# 209
Out of 5,154 analysts
30
Total ratings
52.17%
Success rate
45.54%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Maintains: Outperform | $70 → $118 | $83.49 | +41.33% | 3 | Dec 9, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Outperform | $13 → $16 | $13.30 | +20.30% | 2 | Nov 20, 2025 | |
| ABCL AbCellera Biologics | Downgrades: Market Perform | $4 | $3.45 | +15.94% | 2 | Nov 7, 2025 | |
| GLPG Galapagos NV | Upgrades: Outperform | $29 → $40 | $32.92 | +21.51% | 2 | Oct 21, 2025 | |
| CTNM Contineum Therapeutics | Initiates: Outperform | $20 | $13.88 | +44.09% | 1 | Sep 25, 2025 | |
| ATYR aTyr Pharma | Downgrades: Market Perform | $1 | $0.82 | +21.36% | 2 | Sep 15, 2025 | |
| PTGX Protagonist Therapeutics | Initiates: Outperform | $73 | $92.09 | -20.73% | 1 | Sep 12, 2025 | |
| STTK Shattuck Labs | Maintains: Outperform | $4 → $2 | $5.99 | -66.61% | 2 | Aug 14, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $93.52 | +9.07% | 2 | Jul 10, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $3.50 | -71.43% | 2 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $40.15 | +12.08% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $15.10 | +5.96% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.33 | +50.38% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $74.04 | +8.05% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $6.97 | +115.21% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $16.80 | +167.86% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.53 | +357.52% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.61 | +206.51% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $1.23 | +306.50% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $2.80 | +292.86% | 1 | Mar 21, 2023 |
Kymera Therapeutics
Dec 9, 2025
Maintains: Outperform
Price Target: $70 → $118
Current: $83.49
Upside: +41.33%
Trevi Therapeutics
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $13.30
Upside: +20.30%
AbCellera Biologics
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $3.45
Upside: +15.94%
Galapagos NV
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $32.92
Upside: +21.51%
Contineum Therapeutics
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $13.88
Upside: +44.09%
aTyr Pharma
Sep 15, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.82
Upside: +21.36%
Protagonist Therapeutics
Sep 12, 2025
Initiates: Outperform
Price Target: $73
Current: $92.09
Upside: -20.73%
Shattuck Labs
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $5.99
Upside: -66.61%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $93.52
Upside: +9.07%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $3.50
Upside: -71.43%
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $40.15
Upside: +12.08%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $15.10
Upside: +5.96%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.33
Upside: +50.38%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $74.04
Upside: +8.05%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $6.97
Upside: +115.21%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $16.80
Upside: +167.86%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.53
Upside: +357.52%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $2.61
Upside: +206.51%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $1.23
Upside: +306.50%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $2.80
Upside: +292.86%